Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Ishin Presses Govt to Commit to OTC-Like Drug Reform by FY2026
The Japan Innovation Party (Nippon Ishin) on November 11 urged Prime Minister Sanae Takaichi to formally commit — through a Cabinet decision on the upcoming economic package — to revising out-of-pocket rules for prescription medicines, including so-called “OTC-like” drugs, by…
To read the full story
Related Article
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- MHLW Floats Prefectural Bodies for Regional Formularies, LLP Copay Hike Gains Traction: LDP-Ishin Talks
November 27, 2025
- LDP, Ishin Start Framing Copay Models for OTC-Like Drugs: Bilateral Talks
November 25, 2025
- LDP Outlines Key Issues for FY2026 Budget, Copay Review for OTC-Like Drugs Included
November 21, 2025
- Govt Weighs Additional Copays for OTC-Like Drugs in Economic Package
November 19, 2025
- LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
October 21, 2025
- Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
- 3 Parties Agree to Review OTC-Like Drugs from FY2026, but Details Still in the Air
June 9, 2025
REGULATORY
- Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…